BMC Cardiovascular DisordersBMC心血管疾病
BMC Cardiovascular Disorders(英文缩写 BMC CARDIOVASC DISOR),ISSN 1471-2261,eISSN 1471-2261,中文译名:BMC心血管疾病 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.174 | Q4 |
| 2022 | 2.100 | Q3 |
| 2023 | 2.000 | Q3 |
| 2024 | 2.300 | Q2 |
| 2025 | 3.100 | Q2 |
BMC Cardiovascular Disorders 最新收录文献
-
2. Correction: Bioinformatics analysis of ferroptosis-related hub genes and immunoinfiltration in myocardial ischemia/reperfusion following heart transplantation.
2. 更正：心脏移植后心肌缺血/再灌注中铁死亡相关核心基因及免疫浸润的生物信息学分析PMID:日期:2026-09-21该文献暂无摘要。
-
3. Health-related quality of life, psychological well-being and physical activity in patients with mild-to-moderate ascending aortic dilation - a cross-sectional case-control study.
PMID:日期:2026-09-21To investigate health-related quality of life (HRQoL), psychological well-being and physical activity in patients with mild-to-moderate ascending aortic dilation. While ascending aortic dilation often require lifelong surveillance due to the increased risk of severe complications like aortic dissection or rupture, the impact of living with this known risk on patients' psychological well-being and overall quality of life remains less studied. Subjects with ascending aortic dilation ≥ 40 mm and age- and sex-matched controls were identified in the general population-based Swedish CArdioPulmonary bioImage Study (SCAPIS) in Linköping (n = 5053). Of these, 67 cases and 50 controls completed the questionnaires. HRQoL, psychological well-being, physical activity and capacity were assessed using validated forms. Group comparisons were made with independent t-tests or Mann-Whitney U. For correlation analyses, Spearman's rank correlation was used. No statistically significant differences in quality of life were observed between cases and controls. Anxiety and depression scores were likewise comparable across groups (p = 0.228 and 0.307, respectively). Perceived stress (p = 0.096), physical capacity (p = 0.173), and physical activity (p = 0.471) also did not differ significantly between cases and controls. With respect to sedentary behaviour, cases demonstrated a higher mean rank than controls (62 vs. 52), although the p-value marginally exceeded the conventional threshold for significance (p = 0.062). Finally, no significant correlations were identified between aortic diameter and perceived stress, anxiety, or depression. In this population-based cohort, no statistically significant differences in HRQoL, psychological well-being, and physical activity were observed between subjects with mild to moderate ascending aortic dilation and matched controls. However, given the small sample size, small differences between groups cannot be excluded. Balanced management strategies that promote safe physical activity, psychological well-being and HRQoL remain important in this population.
-
4. Residual lipid-related proteomic and metabolomic signatures associated with major adverse cardiovascular events after revascularization in peripheral artery disease.
PMID:日期:2026-09-17Patients with peripheral artery disease (PAD) remain at high risk for major adverse cardiovascular events (MACE) after lower-extremity revascularization. In contemporary practice, widespread lipid-lowering therapy may reduce the discriminatory value of conventional lipid parameters and clinically defined hyperlipidemia (HLD), leaving residual lipid-related molecular risk insufficiently characterized. This study aimed to characterize residual lipid-related proteomic and metabolomic signatures in PAD and examine their association with MACE after revascularization. We enrolled a prospective cohort of 165 consecutive patients with PAD who underwent lower-extremity endovascular revascularization. Untargeted plasma metabolomic and proteomic profiling was performed. Lipid and lipid-like metabolite coexpression modules were identified using weighted gene coexpression network analysis, and molecular subtypes were defined using nonnegative matrix factorization clustering. Differential metabolites and proteins between subtypes were identified, and a compact multi-omics molecular score was constructed using LASSO regression. Associations with MACE were evaluated using Kaplan-Meier analysis, time-dependent receiver operating characteristic analysis, and multivariable Cox regression. We identified a lipid-related coexpression module associated with HLD but independent of statin use, with enrichment in sphingolipid metabolism, bile acid biosynthesis, and steroid hormone biosynthesis. Molecular clustering stratified patients into two subtypes (C1, n = 64; C2, n = 101) with distinct lipid metabolomic and proteomic profiles. The C1 subtype had significantly poorer MACE-free survival (log-rank P = 0.001). A compact multi-omics score comprising QDPR and four putatively annotated metabolites (deoxycholylphenylalanine, succinylcarnitine, glutarylcarnitine, and acetolein) discriminated between subtypes and was independently associated with MACE (hazard ratio = 1.25, P = 0.032), with a 5-fold cross-validated 15-month AUC of 0.871. Integrated proteomic and metabolomic profiling revealed residual lipid-related molecular signatures beyond conventional lipid parameters in patients with PAD undergoing lower-extremity revascularization. These signatures were associated with subsequent MACE, supporting further validation of molecular biomarkers for postoperative cardiovascular risk stratification in PAD.
-
5. Albumin-based nutritional-inflammatory indices and prognosis in critically ill patients with acute myocardial infarction: a MIMIC-IV cohort study.
PMID:日期:2026-09-17This study investigated the associations between 12 albumin-based nutritional-inflammatory indices and adverse outcomes in critically ill patients with acute myocardial infarction and compared their prognostic performance. A retrospective cohort study was conducted using the MIMIC-IV database, which includes data from 2,255 critically ill AMI patients. Twelve nutritional and inflammatory indices were assessed: Advanced Lung Cancer Inflammation Index (ALI), Blood Urea Nitrogen to Albumin Ratio (BAR), Creatinine to Albumin Ratio (CAR), Controlling Nutritional Status (CONUT) score, Geriatric Nutritional Risk Index (GNRI), Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score, Lactate to Albumin Ratio (LAR), Monocyte to Albumin Ratio (MAR), Neutrophil to Albumin Ratio (NAR), Neutrophil Percentage to Albumin Ratio (NPAR), Prognostic Nutritional Index (PNI), and Red Cell Distribution Width to Albumin Ratio (RAR). The primary outcomes were 30-day and 365-day all-cause mortality (ACM), while secondary outcomes included new-onset atrial fibrillation (NOAF), new-onset ventricular arrhythmia (NOVA), and acute heart failure (AHF). In fully adjusted models, lower levels of GNRI, HALP, and PNI, and higher levels of BAR, CAR, CONUT, LAR, NPAR, and RAR were independently associated with increased 30-day and 365-day ACM. Restricted cubic spline analyses revealed nonlinear relationships for several indices (ALI, BAR, CAR, LAR, PNI). Among the indices evaluated, LAR showed the highest discriminatory performance for 30-day all-cause mortality (AUC = 0.719), whereas BAR showed the highest discriminatory performance for 365-day all-cause mortality (AUC = 0.717). Incremental predictive analyses further supported the additional prognostic information provided by these indices compared with albumin alone. Multiple nutritional indices were significantly associated with both NOAF and NOVA during AMI hospitalization, whereas no significant associations were found with AHF or mechanical complications. However, the findings for mechanical complications should be interpreted cautiously because of the limited number of events. Albumin-based nutritional-inflammatory indices provide additional prognostic information in critically ill patients with acute myocardial infarction. LAR and BAR showed the greatest discriminatory performance for short- and long-term mortality, respectively, but should be considered adjunctive risk-stratification markers rather than stand-alone clinical decision tools.
-
6. The effect of antibacterial mouthwash on blood pressure in humans: a scoping review.
PMID:日期:2026-09-16Oral hygiene is a key component of health. Practices for oral hygiene include brushing teeth with toothpaste, flossing, and mouth washing. It has been reported that 36% of United States adults use mouthwash daily. However, antibacterial mouthwashes kill oral nitrate-reducing bacteria, thus impairing nitric oxide production. Nitric oxide is a key molecule in vasodilation and blood pressure regulation, often acting as a mediator, so there is a potential for antibacterial mouthwashes to cause elevated blood pressure. Therefore, we conducted a scoping review to address the question: Does antibacterial mouthwash use significantly increase blood pressure in humans? A scoping review was conducted utilizing the databases PubMed and Scopus. Our search terms included "mouthwash," "chlorhexidine," "antibacterial," "salivary nitrite," "nitrate," and MeSH terms like "blood pressure" and "hypertension." Inclusion criteria required primary research articles since 2014 that analyzed changes in blood pressure in human adults after using antibacterial mouthwash. Studies with pediatric participants, animal studies, reviews, or studies that did not measure blood pressure changes were excluded. 51 studies were retrieved from the search, and after independent screening by two reviewers, nine studies were included in the scoping review. Reviewers extracted data on study methodology, sample size, participant characteristics, type of mouthwash, mouthwash regimen, and study results. Reviewers also appraised study quality using a modified Downs and Black assessment checklist. Nine studies were included: four randomized crossover trials, three nonrandomized crossover trials, one active-controlled trial, and one observational study. The studies were of good quality (mean modified Downs and Black score was 21.9 ± 2.9 out of 28 points). Five studies found significant blood pressure elevations after mouthwash usage, while four studies found no significant relationship. Heterogeneity in intervention lengths, mouthwash composition, participant characteristics, and blood-pressure assessment schedules, in addition to methodological weaknesses (such as inadequate washout periods and lack of randomization) in some studies make the pooled evidence inconclusive. Consequently, no firm conclusions can be drawn regarding the effect of antibacterial mouthwash on blood pressure at this time. Future research should utilize larger, randomized trials with standard washout periods and long-term monitoring to further clarify the relationship between antibacterial mouthwash usage and blood pressure.
-
7. Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis.
PMID:日期:2026-09-16Bone morphogenetic protein 10 (BMP10) has atrial-specific and vascular properties and may reflect both atrial and vascular pathophysiology. We investigated whether BMP10 levels were associated with new-onset atrial fibrillation (AF), major adverse cardiovascular events (MACE), and all-cause mortality after open revascularisation for symptomatic peripheral arterial disease (PAD) or carotid stenosis (CS). Patients scheduled for endarterectomy for symptomatic PAD or CS were enrolled. BMP10 concentrations were measured using a multiplex immunoassay. Clinical outcomes were obtained from medical records during one-year follow-up. Associations between BMP10 and outcomes were assessed using Cox proportional hazards regression. A total of 210 patients were included (63% men; 61% underwent surgery for PAD). Women were older than men and had higher BMP10 levels. Forty patients had known preoperative AF. During one-year follow-up, 26 patients experienced MACE and 13 died. Among 170 patients without AF at baseline, 10 developed new-onset AF. In unadjusted Cox regression, higher BMP10 levels were associated with MACE (HR 1.01, 95% CI 1.00-1.03; p = 0.047) and all-cause mortality (HR 1.03, 95% CI 1.01-1.04; p < 0.001), but not with new-onset AF (HR 1.00, 95% CI 0.97-1.03; p = 0.80). Effect estimates were similar after adjustment for age and sex. Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations for MACE and all-cause mortality, although confidence intervals were wide; no corresponding pattern was observed for new-onset AF. In this exploratory cohort, higher BMP10 levels were associated with MACE and all-cause mortality after endarterectomy for symptomatic PAD or CS. Women had higher BMP10 levels than men. These findings should be interpreted cautiously and considered hypothesis-generating; larger studies are required to validate the observed associations.
-
8. Opportunistic and systematic screening for atrial fibrillation in adults aged ≥ 65 years in primary care: a systematic review of randomized and cluster randomized trials.
PMID:日期:2026-09-11To evaluate whether opportunistic atrial fibrillation (AF) screening in adults aged ≥ 65 years improves AF detection and clinical outcomes compared with usual care, and to compare opportunistic and systematic screening strategies in terms of AF detection and clinical outcomes. A systematic review was conducted in accordance with PRISMA 2020 guidelines. Randomized and cluster-randomized controlled trials evaluating opportunistic or systematic AF screening in adults aged ≥ 65 years were included. Electronic databases (MEDLINE, Embase, and CENTRAL) were searched from inception to December 2024. Studies with sufficiently comparable outcome data were included in a structured descriptive quantitative synthesis of AF detection rates. Because of substantial clinical and methodological heterogeneity among the included studies, a pooled meta-analysis was not performed. Instead, study-level outcomes were summarized descriptively. Studies with heterogeneous designs or outcome reporting were synthesized narratively. Outcomes of interest included AF detection, initiation of oral anticoagulation, stroke incidence, and all-cause mortality. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Study selection and data extraction were performed independently by two reviewers. Nine randomized or cluster-randomized trials were included. Both opportunistic and systematic screening approaches were associated with increased detection of previously undiagnosed AF compared with usual care. Opportunistic screening increased AF detection in several trials; however, direct comparisons with systematic approaches should be interpreted cautiously because of heterogeneity in monitoring intensity, follow-up duration, and population characteristics. Studies employing prolonged or continuous monitoring generally yielded higher AF detection rates; however, direct comparisons with opportunistic screening should be interpreted cautiously because of differences in monitoring intensity, follow-up duration, and population characteristics. Anticoagulation initiation varied across studies. Across studies, no consistent reduction in stroke incidence or all-cause mortality was observed. Most trials were judged to have some concerns regarding risk of bias, primarily related to pragmatic trial designs. Because AF diagnosis was confirmed using objective electrocardiographic criteria, the risk of outcome measurement bias was generally low. AF screening increases detection of previously undiagnosed AF in older adults. Opportunistic screening may be more readily integrated into routine healthcare encounters than organized systematic screening programs; however, implementation outcomes and cost-effectiveness were not consistently evaluated across the included trials. Current randomized evidence does not demonstrate consistent improvement in clinical outcomes such as stroke reduction or mortality, highlighting the need for further high-quality randomized trials evaluating integrated screening and post-detection care pathways.
-
9. Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials.
PMID:日期:2026-09-10Inflammation contributes significantly to cardiovascular disease progression. While both atorvastatin and rosuvastatin have anti-inflammatory effects, evidence directly comparing their effects on inflammatory biomarkers is limited and inconsistent. This study aimed to compare their effects through a meta-analysis of randomized controlled trials (RCTs). We performed a systematic review and meta-analysis of head-to-head RCTs comparing atorvastatin and rosuvastatin on inflammatory biomarkers. On August 14, 2024, we searched PubMed, Web of Science, Scopus, and CENTRAL, and subsequently searched ClinicalTrials.gov for unpublished studies. We included RCTs directly comparing the two statins and reported changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), or adiponectin. Using a random-effects model, we pooled the data and reported the results as mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals (CIs). We assessed risk of bias using the Cochrane RoB 2 tool. The review protocol was registered in PROSPERO (CRD42024579712) (see the PRISMA 2020 for Abstracts checklist). A total of 35 RCTs (n = 6,148) were included. The pooled effect showed no significant difference in CRP reduction (MD: - 0.53 mg/L; 95% CI: - 1.10 to 0.05; p = 0.07; I = 82%). After excluding one outlier, rosuvastatin showed a greater reduction (MD: - 0.16 mg/L; 95% CI: - 0.28 to - 0.03; p = 0.01; I = 63%). The SMD also favored rosuvastatin (SMD: - 0.17; 95% CI: - 0.31 to - 0.04; p = 0.01). Sensitivity analysis among low risk-of-bias studies (n = 9) showed a smaller yet significant reduction (MD: - 0.08 mg/L; 95% CI: - 0.16 to - 0.01; p = 0.03). We observed no significant differences for IL-6 (n = 484; MD: - 0.82; 95% CI: - 3.02 to 1.38), adiponectin (n = 257; MD: - 1.78; 95% CI: - 4.70 to 1.14), or TNF-alpha (n = 309; MD: 0.23; 95% CI: - 0.05 to 0.52). Meta-regression identified baseline CRP, HDL, and hypertension prevalence as predictors of CRP reduction. Rosuvastatin showed a modest but statistically significant advantage over atorvastatin in lowering CRP, especially in patients with higher baseline inflammation or hypertension. Evidence for other biomarkers remains inconclusive. Tailoring statin therapy to patient profiles may optimize benefits.
-
10. Telmisartan-based monotherapy and combination regimens for blood pressure control in adults with hypertension: a systematic review, meta-analysis, and GRADE assessment.
PMID:日期:2026-09-03To evaluate the efficacy, safety, and certainty of evidence for telmisartan-based antihypertensive regimens in adults with hypertension. This systematic review and meta-analysis followed PRISMA 2020. PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception to 2026. Eligible studies enrolled adults with hypertension and compared telmisartan monotherapy or telmisartan-containing combinations with placebo, usual care, non-telmisartan antihypertensive agents, or alternative telmisartan-based regimens. Continuous outcomes were pooled as mean differences (MDs) and dichotomous outcomes as risk ratios (RRs), both with 95% confidence intervals (CIs), using random-effects models, with additional subgroup analyses conducted by comparator type. Risk of bias was assessed using RoB 2, and certainty of evidence was evaluated using GRADE. Twenty-five included reports (24 unique trials, since two reports present secondary outcomes from the same underlying trial) involving 6,521 participants were included, spanning placebo-controlled, usual-care-controlled, active-comparator, and telmisartan-combination-versus-telmisartan-monotherapy designs. Telmisartan-based therapy significantly reduced office systolic blood pressure (MD - 6.39 mm Hg; 95% CI - 7.86 to - 4.93; low certainty) and office diastolic blood pressure (MD - 4.88 mm Hg; 95% CI - 6.67 to - 3.09; low certainty), although the magnitude of effect was comparator-dependent. Based on only two trials, 24-h ambulatory systolic blood pressure (MD - 7.16 mm Hg; 95% CI - 10.61 to - 3.72) and ambulatory diastolic blood pressure (MD - 4.42 mm Hg; 95% CI - 6.36 to - 2.48) were reduced with moderate certainty. Telmisartan-based regimens improved blood pressure response (RR 1.68; 95% CI 1.31 to 2.16; moderate certainty) but not blood pressure control achievement (RR 1.44; 95% CI 0.92 to 2.24; very low certainty). Overall adverse events, dizziness, and headache were comparable (very low to low certainty), while edema was less frequent with telmisartan-based therapy (RR 0.33; 95% CI 0.15 to 0.73; moderate certainty). Telmisartan-based regimens, particularly fixed-dose and multidrug combinations, effectively reduce office and ambulatory blood pressure and improve blood pressure response, with broadly comparable short-term safety and less edema. These effect sizes are comparator-dependent, and certainty of evidence for absolute blood pressure control achievement and for major adverse events is very low; heterogeneity, limited long-term data, and a predominance of Asian-population trials warrant cautious interpretation pending larger, higher-quality, and more geographically diverse confirmatory studies.